Skip to main content

Adoptive engineered T cell Trials to Achieve Cancer Killing

Objective

The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials needed. This proposal builds upon previous EU funded pre-clinical projects and comprises a multidisciplinary and translational research group with wide-ranging relevant expertise. Building on encouraging clinical results targeting NY-ESO-1 in melanoma and the availability of clinical grade vector, the consortium proposes to rapidly initiate two landmark studies in this field: the first to examine the activity of engineered T cells in oesophago-gastric cancer as an example of a hard to treat common epithelial cancer; the second to undertake a randomised phase II study to determine whether an optimised cell production system developed by the partners improves the current clinical response rates in patients with metastatic melanoma treated with NY-ESO-1 targeted T-cells. Success in these trials will enable the consortia and others to carryout larger trials and potentially approval of this type of therapy as a treatment for multiple cancer types. The inclusion of a major industrial partner focused on cell therapy technology and two SMEs focus on the delivery of cell therapy will facilitate future development of this area following these trials; indeed the project also includes plans to further automate and streamline cell processing to facilitate this development. This project would enhance European expertise and competitiveness in an important emerging market. The research will also support the European biotechnology industry which will be important for the exploitation of these therapies and the successful outcome of this project.

Field of science

  • /natural sciences/biological sciences/biochemistry/biomolecules/nucleic acid
  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/clinical medicine/dermatology/melanoma
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

THE UNIVERSITY OF MANCHESTER
Address
Oxford Road
M13 9PL Manchester
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 578 497,20
Administrative Contact
Robert Hawkins (Prof.)

Participants (15)

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 301 000,40
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Reno Debets (Dr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 39 000
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Maria Von Witting (Mrs.)
FONDAZIONE CENTRO SAN RAFFAELE

Participation ended

Italy
Address
Via Olgettina 60
20132 Milano
Activity type
Research Organisations
Administrative Contact
Maria Rosa Pedrazzi (Dr.)
THE CHRISTIE NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 666 000,40
Address
Wilmslow Road 1
M20 4BX Manchester
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Angela Ball
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 266 000,40
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
William Lepetit (Mr.)
CELLULAR THERAPEUTICS LIMITED
United Kingdom
EU contribution
€ 1 287 000
Address
Hawthorn Lane 34 Heald Court 3
SK9 5DG Wilmslow
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ryan Guest (Dr.)
ROYAL FREE LONDON NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 122 000,20
Address
Pond Street Hampstead
NW3 2QG London
Activity type
Research Organisations
Administrative Contact
Anna Jones (Ms.)
MILTENYI BIOTEC GMBH
Germany
EU contribution
€ 405 500
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sabrina Schmitz (Ms.)
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
EU contribution
€ 266 000,40
Address
Plesmanlaan 121
1066 CX Amsterdam
Activity type
Research Organisations
Administrative Contact
Sander Berghuis (Mr.)
AMSTERDAM BIOTHERAPEUTICS UNIT
Netherlands
EU contribution
€ 1 091 000
Address
Louwesweg 6
1066EC Amsterdam
Activity type
Research Organisations
Administrative Contact
Bastiaan Nuijen (Dr.)
ADAPTIMMUNE LIMITED
United Kingdom
EU contribution
€ 306 000
Address
Garsington Road 9400 Oxford Business Park
OX4 2HN Oxford
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dan Williams (Dr.)
UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 122 000,20
Address
Euston Road 250
NW1 2PG London
Activity type
Research Organisations
Administrative Contact
Emma Clark (Ms.)
REGION STOCKHOLM
Sweden
EU contribution
€ 262 000,40
Address
Hantverkargatan 45
104 22 Stockholm
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Rolf Kiessling (Prof.)
UCL Elizabeth Garrett Anderson Institute for Women’s Health
United Kingdom
EU contribution
€ 22 000
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Greta Borg-Carbott (Ms.)
OSPEDALE SAN RAFFAELE SRL
Italy
EU contribution
€ 266 000,40
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Maria Rosa Pedrazzi (Dr.)